BFRI· Health Care› Drug Manufacturers - Specialty & Generic

Biofrontera Inc.

Stage 3 · Topping · week 2

As of Oct 22, 2026, Biofrontera is in Stage 3, the topping phase, now in week 2 (since Oct 12, 2026). It closed at $0.78, 51.5% below its 52-week high and below its 200-day average, which is rising.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. More about the company

$0.78

-12.25% today

$11.6M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is BFRI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 32w

S4 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 3w → S4 32w → S1 7w → S4 10w → S1 8w → S4 10w → S1 7w → S2 4w → S3 1w → S4 17w → S1 6w → S2 13w → S3 6w → S4 5w → S1 3w → S2 2w → S1 4w → S2 11w → S3 3w → S2 10w → S3 2w current

Total tracked: 165 weeks across 21 stage runs.

BFRI among Drug Manufacturers - Specialty & Generic42nd of 84 by relative strength

All 84 →

Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CPIXCumberland Pharmaceuticals Inc.	Stage 2 · wk 23	98	+6.8%
2	ETONEton Pharmaceuticals, Inc.	Stage 2 · wk 30	97	−10.1%
3	ANIKAnika Therapeutics Inc.	Stage 2 · wk 15	96	+3.5%
4	IRWDIronwood Pharmaceuticals, Inc. Class A	Stage 3 · wk 3	96	−16.4%
5	TEVATeva Pharmaceutical Industries Limited	Stage 2 · wk 9	95	+3.1%
6	AMRXAmneal Pharmaceuticals, Inc. Class A	Stage 2 · wk 19	95	+5.9%
7	KNSAKiniksa Pharmaceuticals International, plc Class A	Stage 2 · wk 73	95	+6.2%
8	AMLXAmylyx Pharmaceuticals, Inc.	Stage 2 · wk 15	93	−6.6%
…42	BFRIBiofrontera Inc.	Stage 3 · wk 2	39	−32.1%

vs 52W High

-51.5%

$0.57 lo$1.61 hi

51.5% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 2

1w13w26w

Week 2, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-24.4%

200 DMA: $1.03 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.28x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-32.1%

-28.3%

-24.2%

YTD

+7.7%

-21.7%

Scan Membership

Breakout Watch

Latest: 2025-02-14

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 2 · Vol 0.28x

2026-10-21S3

Wk 2 · Vol 0.22x

2026-10-20S3

Wk 2 · Vol 0.12x

2026-10-19S3

Wk 2 · Vol 0.25x

2026-10-16S3

Wk 1 · Vol 0.34x

2026-10-15S3

Wk 1 · Vol 0.47x

2026-10-14S3

Wk 1 · Vol 0.58x

2026-10-13S3

Wk 1 · Vol 0.54x

2026-10-12S32→3

Wk 1 · Vol 0.23x

2026-10-09S2

Wk 11 · Vol 0.45x

2026-10-08S2

Wk 11 · Vol 0.37x

2026-10-07S2

Wk 10 · Vol 0.44x

Moving averages & range

50 DMA

$1.22

200 DMA

$1.03

52W High

$1.61

52W Low

$0.57

5D Low

$0.78

Resistance levels (recent highs)

20d High

$1.18

60d High

$1.61

120d High

$1.61

250d High

$1.61

Next resistance

+51.1%

to 20d High

ROE

-988.4%

Profit margin -13.8%

Dividend Yield

0.00%

P/B 1.9

Biofrontera: quick answers

What stage is Biofrontera in?

As of Oct 22, 2026, Biofrontera (BFRI) is in Stage 3, the topping phase. It entered Stage 3 on Oct 12, 2026 and is in week 2. What the four stages mean

Is Biofrontera in an uptrend?

Its uptrend has stalled. Biofrontera is in Stage 3, the topping phase that follows an advance. It trades 24.4% below its 200-day average, which is rising.

How far is Biofrontera from its 52-week high?

Biofrontera closed at $0.78 on Oct 22, 2026, 51.5% below its 52-week high of $1.61. Its 52-week low is $0.57.

How has Biofrontera performed over the past year?

As of Oct 22, 2026, Biofrontera is down 21.7% over the past year and up 7.7% so far in 2026.

Which sector and industry is Biofrontera in?

Biofrontera is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.